News coverage about Alnylam Pharmaceuticals (NASDAQ:ALNY) has been trending somewhat positive this week, according to AlphaOne Sentiment. AlphaOne, a unit of Accern, identifies negative and positive media coverage by analyzing more than 20 million news and blog sources. AlphaOne ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Alnylam Pharmaceuticals earned a daily sentiment score of 0.18 on AlphaOne’s scale. AlphaOne also gave news articles about the biopharmaceutical company an impact score of 26 out of 100, indicating that recent media coverage is unlikely to have an effect on the company’s share price in the immediate future.
Here are some of the news articles that may have impacted AlphaOne Sentiment Analysis’s analysis:
- Alnylam Pharmaceuticals (ALNY) Receiving Favorable News Coverage, Analysis Shows (americanbankingnews.com)
- Alnylam Pharmaceuticals, Inc. – Value Analysis (NASDAQ:ALNY) : April 20, 2017 (finance.yahoo.com)
- Alnylam Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : ALNY-US : April 19, 2017 (finance.yahoo.com)
- RNA – based Therapeutics and Vaccines Market Estimated to Flourish by 2016 – 2024 : Persistence Market Research (openpr.com)
- Deltic Timber (DEL) Trades at $75.16 After Triangle, Last Week Alnylam Pharmaceuticals, Inc. (ALNY) Analysts – UtahHerald.com (utahherald.com)
Shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) traded down 1.021% during mid-day trading on Friday, reaching $49.945. The company’s stock had a trading volume of 230,670 shares. The company’s 50-day moving average price is $51.37 and its 200-day moving average price is $44.53. Alnylam Pharmaceuticals has a 12-month low of $31.38 and a 12-month high of $80.11. The stock’s market capitalization is $4.30 billion.
Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings results on Wednesday, February 8th. The biopharmaceutical company reported ($1.32) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.34) by $0.02. The company had revenue of $17.50 million for the quarter, compared to the consensus estimate of $10.66 million. Alnylam Pharmaceuticals had a negative return on equity of 37.25% and a negative net margin of 869.63%. Alnylam Pharmaceuticals’s revenue for the quarter was up 130.3% on a year-over-year basis. During the same quarter in the prior year, the business posted ($1.07) earnings per share. On average, equities research analysts forecast that Alnylam Pharmaceuticals will post ($5.16) earnings per share for the current fiscal year.
Several analysts recently issued reports on the stock. BMO Capital Markets assumed coverage on shares of Alnylam Pharmaceuticals in a research report on Monday. They issued an “outperform” rating and a $73.00 price target for the company. Credit Suisse Group AG downgraded shares of Alnylam Pharmaceuticals to a “hold” rating and set a $50.00 price objective on the stock. in a report on Monday, March 20th. FBR & Co reissued a “buy” rating on shares of Alnylam Pharmaceuticals in a report on Monday, March 20th. Vetr raised shares of Alnylam Pharmaceuticals from a “strong sell” rating to a “strong-buy” rating and set a $72.50 price target on the stock in a report on Thursday, March 16th. Finally, Needham & Company LLC restated a “buy” rating and issued a $68.00 price objective (down from $98.00) on shares of Alnylam Pharmaceuticals in a research note on Thursday, February 9th. Eight investment analysts have rated the stock with a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the stock. Alnylam Pharmaceuticals currently has an average rating of “Buy” and a consensus price target of $64.97.
In other Alnylam Pharmaceuticals news, Director Philip A. Sharp sold 15,000 shares of the stock in a transaction that occurred on Wednesday, January 25th. The stock was sold at an average price of $37.95, for a total transaction of $569,250.00. Following the transaction, the director now owns 155,795 shares in the company, valued at $5,912,420.25. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 4.00% of the company’s stock.
About Alnylam Pharmaceuticals
Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).
Receive News & Ratings for Alnylam Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.